Cargando…
S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428433/ http://dx.doi.org/10.1097/01.HS9.0000967316.99954.0c |
| _version_ | 1785090468104634368 |
|---|---|
| author | Della Porta, Matteo Giovanni Platzbecker, Uwe Santini, Valeria Zeidan, Amer M. Fenaux, Pierre Komrokji, Rami S. Shortt, Jake Valcárcel, David Jonášová, Anna Dimicoli-Salazar, Sophie Tiong, Ing Soo Lin, Chien-Chin LI, Jiahui Zhang, Jennie Carolina Giuseppi, Ana Kreitz, Sandra Pozharskaya, Veronika Keeperman, Karen L. Rose, Shelonitda Shetty, Jeevan K. Hayati, Sheida Vodala, Sadanand Degulys, Andrius Paolini, Stefania Cluzeau, Thomas Garcia-Manero, Guillermo |
| author_facet | Della Porta, Matteo Giovanni Platzbecker, Uwe Santini, Valeria Zeidan, Amer M. Fenaux, Pierre Komrokji, Rami S. Shortt, Jake Valcárcel, David Jonášová, Anna Dimicoli-Salazar, Sophie Tiong, Ing Soo Lin, Chien-Chin LI, Jiahui Zhang, Jennie Carolina Giuseppi, Ana Kreitz, Sandra Pozharskaya, Veronika Keeperman, Karen L. Rose, Shelonitda Shetty, Jeevan K. Hayati, Sheida Vodala, Sadanand Degulys, Andrius Paolini, Stefania Cluzeau, Thomas Garcia-Manero, Guillermo |
| author_sort | Della Porta, Matteo Giovanni |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428433 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284332023-08-17 S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY Della Porta, Matteo Giovanni Platzbecker, Uwe Santini, Valeria Zeidan, Amer M. Fenaux, Pierre Komrokji, Rami S. Shortt, Jake Valcárcel, David Jonášová, Anna Dimicoli-Salazar, Sophie Tiong, Ing Soo Lin, Chien-Chin LI, Jiahui Zhang, Jennie Carolina Giuseppi, Ana Kreitz, Sandra Pozharskaya, Veronika Keeperman, Karen L. Rose, Shelonitda Shetty, Jeevan K. Hayati, Sheida Vodala, Sadanand Degulys, Andrius Paolini, Stefania Cluzeau, Thomas Garcia-Manero, Guillermo Hemasphere Plenary Abstracts Session Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428433/ http://dx.doi.org/10.1097/01.HS9.0000967316.99954.0c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Plenary Abstracts Session Della Porta, Matteo Giovanni Platzbecker, Uwe Santini, Valeria Zeidan, Amer M. Fenaux, Pierre Komrokji, Rami S. Shortt, Jake Valcárcel, David Jonášová, Anna Dimicoli-Salazar, Sophie Tiong, Ing Soo Lin, Chien-Chin LI, Jiahui Zhang, Jennie Carolina Giuseppi, Ana Kreitz, Sandra Pozharskaya, Veronika Keeperman, Karen L. Rose, Shelonitda Shetty, Jeevan K. Hayati, Sheida Vodala, Sadanand Degulys, Andrius Paolini, Stefania Cluzeau, Thomas Garcia-Manero, Guillermo S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY |
| title | S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY |
| title_full | S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY |
| title_fullStr | S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY |
| title_full_unstemmed | S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY |
| title_short | S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY |
| title_sort | s102: luspatercept versus epoetin alfa for treatment (tx) of anemia in esa-naive lower-risk myelodysplastic syndromes (lr-mds) patients (pts) requiring rbc transfusions: data from the phase 3 commands study |
| topic | Plenary Abstracts Session |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428433/ http://dx.doi.org/10.1097/01.HS9.0000967316.99954.0c |
| work_keys_str_mv | AT dellaportamatteogiovanni s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT platzbeckeruwe s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT santinivaleria s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT zeidanamerm s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT fenauxpierre s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT komrokjiramis s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT shorttjake s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT valcarceldavid s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT jonasovaanna s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT dimicolisalazarsophie s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT tiongingsoo s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT linchienchin s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT lijiahui s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT zhangjennie s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT carolinagiuseppiana s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT kreitzsandra s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT pozharskayaveronika s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT keepermankarenl s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT roseshelonitda s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT shettyjeevank s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT hayatisheida s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT vodalasadanand s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT degulysandrius s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT paolinistefania s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT cluzeauthomas s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy AT garciamaneroguillermo s102luspaterceptversusepoetinalfafortreatmenttxofanemiainesanaivelowerriskmyelodysplasticsyndromeslrmdspatientsptsrequiringrbctransfusionsdatafromthephase3commandsstudy |